Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

Article ID	Journal	Published Year	Pages	File Type
6118986	Joint Bone Spine	2014	8 Pages	PDF

Abstract

Etanercept had a better retention rate than adalimumab and infliximab as first-line biotherapy in RA, and than adalimumab as second-line biotherapy.

Keywords

Adalimumab TNF-α inhibitors Rheumatoid arthritis etanercept Infliximab Retention rate

Related Topics

Health Sciences Medicine and Dentistry Immunology, Allergology and Rheumatology

Preview

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

Authors

Aline Frazier-Mironer, Maxime Dougados, Xavier Mariette, Alain Cantagrel, Véronique Deschamps, René Marc Flipo, Isabelle Logeart, Thierry Schaeverbeke, Jean Sibilia, Xavier Le Loët, Bernard Combe,